-transparent.png){kind=logo}
In a double-blind, placebo-controlled study nasal saline and histamine provocation tests were performed in patients with perennial allergic rhinitis in order to assess changes in eosinophil influx and non-specific nasal reactivity after 8 days of treatment with ipratropium bromide. A "nasal pool" method was used to trace changes in protein level and eosinophil influx into nasal secretions. Treatment with ipratropium 80 mg q.i.d. caused a significant decrease in the albumin and total protein level in saline washings and induced a five-fold increase in eosinophils as compared to the placebo treatment. The nasal mucosal response to histamine, assessed as the number of sneezes and protein level, was more responsive to ipratropium treatment than the mucosa from placebo-treated subjects. Since eosinophil numbers were correlated with an increase in the vascular and sneezing responses, it appears that ipratropium potentiates inflammatory mechanisms when used in subjects with an allergy in the nasal mucosa.
P Górski, and
K Pazdrak, and
U Ruta
May 1997,
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
P Górski, and
K Pazdrak, and
U Ruta
May 1995,
The Journal of allergy and clinical immunology,
P Górski, and
K Pazdrak, and
U Ruta
January 1979,
Acta oto-laryngologica. Supplementum,
P Górski, and
K Pazdrak, and
U Ruta
January 1995,
Auris, nasus, larynx,
P Górski, and
K Pazdrak, and
U Ruta
January 1998,
American journal of rhinology,
P Górski, and
K Pazdrak, and
U Ruta
January 2012,
Mediators of inflammation,
P Górski, and
K Pazdrak, and
U Ruta
November 2020,
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,
P Górski, and
K Pazdrak, and
U Ruta
January 1983,
European journal of respiratory diseases. Supplement,
P Górski, and
K Pazdrak, and
U Ruta
October 1997,
The Annals of otology, rhinology, and laryngology,
P Górski, and
K Pazdrak, and
U Ruta
June 1997,
Asian Pacific journal of allergy and immunology,
